Browsing Tag
NASDAQ
806 posts
Is Docusign finally proving that AI can revive its post-pandemic growth story?
Find out how Docusign’s AI agreement platform is reshaping its fiscal 2027 growth outlook and what it means for DOCU stock.
Can CXAI’s EngineRoom acquisition turn agentic AI demand into a stronger revenue story?
Find out how CXAI’s EngineRoom acquisition could reshape agentic AI revenue growth, dilution risk, and investor sentiment.
Could Quantinuum’s upsized IPO become a major test of public-market appetite for quantum computing stocks?
Find out how Quantinuum’s $1.68bn IPO could test investor appetite for quantum computing stocks as QNT begins trading on Nasdaq.
SpaceX (SPCX) targets $1.75tn in record IPO, but Morningstar pegs fair value at $780bn
SpaceX set a fixed $135/share for a record $75B IPO at a $1.75T valuation, but Morningstar pegs fair value at $780B. ARK says $2.5T by 2030. The valuation gap is huge.
EU opens deeper probe into JD.com’s CECONOMY deal as Chinese M&A faces tougher subsidy scrutiny
JD.com wants European retail scale. Brussels wants proof the CECONOMY deal is not subsidy-backed. The October decision now matters.
Could Gorilla Technology’s $2bn India AI deal turn GRRR into a sovereign AI infrastructure stock?
Find out how Gorilla Technology’s $2 billion India AI deal with Supermicro could reshape GRRR stock sentiment and sovereign AI infrastructure.
Can LightPath Technologies justify its $100m offering as LPTH investors weigh dilution risk?
Find out how LightPath Technologies’ $100 million stock offering could affect LPTH dilution risk, defense optics growth, and investor sentiment.
Could CME Group’s 24/7 crypto derivatives push defend its exchange moat as CME stock slides?
Find out how CME Group’s 24/7 crypto derivatives launch could reshape regulated digital asset trading as CME stock faces pressure.
Could Akamai Technologies’ NVIDIA collaboration make AI factory security a bigger enterprise priority?
Find out how Akamai Technologies’ NVIDIA collaboration could reshape AI factory security, distributed cloud growth, and AKAM stock sentiment.
Moderna (MRNA) and Merck (MRK) cancer vaccine sustains benefit at five years, but investors stay cautious
Moderna and Merck's mRNA cancer vaccine sustained a 49% reduction in melanoma recurrence at five years, but MRNA fell as investors weigh near-term pressures.